South Korea to Brief Lawmakers on $350 Billion US Investment Package 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
White House Bars CNN, MS NOW and Politico Reporters 
Volkswagen Shares Slide After 2026 Profit Outlook Cut 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center 
Vietnam Stocks Join FTSE Emerging Market Indexes, Unlocking Billions in Foreign Investment 
Yen in Focus as BOJ, Fed Rate Hikes Reshape Currency Markets 
Wall Street Mixed as Treasury Yields Rise After Fed Hike 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
OpenAI Urges US-Led Global Standards for Frontier AI 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
Gold Prices Slip as Strong Dollar and Hawkish Fed Pressure Bullion 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
Add as a preferred source on Google
Samsung Biologics and TG Therapeutics will continue working together as they just renewed their drug manufacturing deal. The contract will allow the South Korean biotechnology firm to produce more drugs for the US-based healthcare company.
The expansion of Samsung Biologics and TG Therapeutics CMO deal
As per The Korea Times, the two companies agreed to sign another deal for the supply of Ublituximab, an investigational monoclonal antibody drug for the treatment of multiple sclerosis. The new contract manufacturing organization (CMO) deal is worth $50.3 million, which is more than double of their previous deal that was only priced at $22.4 million.
This is Samsung Biologics and TG Therapeutics fourth partnership since they teamed up in February 2018. All of their first three contracts were also for the production and supply of Ublituximab.
“We are very glad to be able to flexibly accommodate our client’s expanded needs through our facilities,” Samsung Biologics chief executive officer, John Rim, said in a press release. “By supporting TG Therapeutics in this partnership, we are contributing to bringing needed treatments to patients around the world and getting a step closer to our vision of bringing about a better life for humanity.”
Looking forward to the success of the Ublituximab drug
TG Therapeutics has been developing Ublituximab for a while now, and the company already requested for biologics license by submitting an application to the U.S. Food and Drug Administration (FDA). The said drug is in the third phase of testing, so it is crucial for the license to be approved.
In any case, Samsung Biologics mainly provides manufacturing, development, and testing services to its clients. The company helps them meet the demand through CMO deals, and as it continues to receive new contracts, it is now building its fourth manufacturing plant in Incheon, and so far, this will be the Samsung Biologics’ largest facility.
Meanwhile, once TG Therapeutics finally received its license and its drug development for Ublituximab is successful, Samsung Biologics is reportedly guaranteed a minimum contract worth $278.1 million. This price can potentially go up to $345.6 million if the American healthcare firm makes more drugs.
"Samsung is the global leader in biologics manufacturing and we are happy to have them as our partner as we look forward to the potential commercialization of Ublituximab across both oncology and autoimmune indications," Michael S. Weiss, TG Therapeutics CEO, said.
